Status:

COMPLETED

Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

Lead Sponsor:

Mayo Clinic

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Melanoma (Skin)

Eligibility:

All Genders

18-120 years

Phase:

PHASE1

Brief Summary

RATIONALE: Monoclonal antibodies can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing s...

Detailed Description

OBJECTIVES: Primary * Determine the safety/toxicity of a single dose of B7-dendritic cell cross-linking antibody containing plasma in treating patients with stage IV melanoma. Secondary * Describe...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Histologically confirmed melanoma
  • Stage IV disease (M1a and M1b only)
  • Measurable disease according to RECIST criteria
  • HLA-A2 positive
  • Must have IgA in serum (any concentration)
  • No known standard therapy for this disease that is potentially curative or proven capable of extending life expectancy
  • PATIENT CHARACTERISTICS:
  • ECOG performance status 0-2
  • Hemoglobin ≥ 10.0 g/dL
  • Platelet count ≥ 75,000/mm\^3
  • AST ≤ 5 times upper limit of normal
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Able to provide informed consent
  • Agrees to return to Mayo Clinic Rochester for follow-up
  • Agrees to participate in the mandatory translational research component of the study
  • No uncontrolled or current infection
  • No known immune deficiency
  • No B or AB blood grouping
  • PRIOR CONCURRENT THERAPY:
  • More than 4 weeks since prior chemotherapy and recovered
  • More than 4 weeks since prior biologic therapy
  • No concurrent immunosuppressive therapy

Exclusion

    Key Trial Info

    Start Date :

    April 8 2008

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    May 22 2012

    Estimated Enrollment :

    7 Patients enrolled

    Trial Details

    Trial ID

    NCT00658892

    Start Date

    April 8 2008

    End Date

    May 22 2012

    Last Update

    May 25 2017

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Mayo Clinic

    Rochester, Minnesota, United States, 55905

    Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma | DecenTrialz